Main Navigation

• The Children's Inn
• National Cancer Institute, Childhood Cancers
• NIH Clinical Center
• Camp Fantastic

Pediatric Oncology Branch Home > Scientific Programs > Pharmacology and Experimental Therapeutics Section and Genetic Tumor Predisposition Program > Recent Publications

Headline Title

Pharmacology & Experimental Therapeutics

Recent Publications from 2008 - 2010:

1. Widemann BC, Goodspeed W, Goodwin A, Fojo T, Balis FM, Fox E: Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors. J Clin Oncol 27:550-6, 2009

2. Widemann BC: Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Curr Oncol Rep 11:322-8, 2009

3. Meany HJ, Warren KE, Fox E, Cole DE, Aikin AA, Balis FM: Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors. Cancer Chemother Pharmacol 65:137-42, 2009

4. Kim A, Gillespie A, Dombi E, Goodwin A, Goodspeed W, Fox E, Balis FM, Widemann BC: Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas. Neurology 73:1273-9, 2009

5. Kim A, Balis FM, Widemann BC: Sorafenib and sunitinib. Oncologist 14:800-5, 2009

6. Fox E, Widemann BC, Hawkins DS, Jayaprakash N, Dagher R, Aikin AA, Bernstein D, Long L, Mackall C, Helman L, Steinberg SM, Balis FM: Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas. Clin Cancer Res 15:7361-7, 2009

7. Evans DG, Kalamarides M, Hunter-Schaedle K, Blakeley J, Allen J, Babovic-Vuskanovic D, Belzberg A, Bollag G, Chen R, DiTomaso E, Golfinos J, Harris G, Jacob A, Kalpana G, Karajannis M, Korf B, Kurzrock R, Law M, McClatchey A, Packer R, Roehm P, Rubenstein A, Slattery W, 3rd, Tonsgard JH, Welling DB, Widemann B, Yohay K, Giovannini M: Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. Clin Cancer Res 15:5032-9, 2009

8. Chuk MK, Balis FM, Fox E: Trabectedin. Oncologist 14:794-9, 2009

9. Balis FM, Fox E, Widemann BC, Adamson PC: Clinical drug development for childhood cancers. Clin Pharmacol Ther 85:127-9, 2009

10. Mautner VF, Asuagbor FA, Dombi E, Funsterer C, Kluwe L, Wenzel R, Widemann BC, Friedman JM: Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1. Neuro Oncol 10:593-8, 2008

11. Kim A, Fox E, Warren K, Blaney SM, Berg SL, Adamson PC, Libucha M, Byrley E, Balis FM, Widemann BC: Characteristics and outcome of pediatric patients enrolled in phase I oncology trials. Oncologist 13:679-89, 2008

12. Fox E, Razzouk BI, Widemann BC, Xiao S, O'Brien M, Goodspeed W, Reaman GH, Blaney SM, Murgo AJ, Balis FM, Adamson PC: Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. Blood 111:566-73, 2008

13. Fox E, Maris JM, Widemann BC, Goodspeed W, Goodwin A, Kromplewski M, Fouts ME, Medina D, Cohn SL, Krivoshik A, Hagey AE, Adamson PC, Balis FM: A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors. Clin Cancer Res 14:1111-5, 2008

14. Fisher MJ, Basu S, Dombi E, Yu JQ, Widemann BC, Pollock AN, Cnaan A, Zhuang H, Phillips PC, Alavi A: The role of [18F]-fluorodeoxyglucose positron emission tomography in predicting plexiform neurofibroma progression. J Neurooncol 87:165-71, 2008

15. Meany HJ, Sackett DL, Maris JM, Ward Y, Krivoshik A, Cohn SL, Steinberg SM, Balis FM, Fox E: Clinical outcome in children with recurrent neuroblastoma treated with ABT-751 and effect of ABT-751 on proliferation of neuroblastoma cell lines and on tubulin polymerization in vitro. Pediatr Blood Cancer 54:47-54

16. Meany H, Balis FM, Aikin A, Whitcomb P, Murphy RF, Steinberg SM, Widemann BC, Fox E: Pediatric Phase I Trial Design Using Maximum Target Inhibition as the Primary Endpoint. J Natl Cancer Inst

17. Jacobs S, Fox E, Krailo M, Hartley G, Navid F, Wexler L, Blaney SM, Goodwin A, Goodspeed W, Balis FM, Adamson PC, Widemann BC: Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group. Clin Cancer Res 16:750-4

18. Fox E, Maris JM, Cohn SL, Goodspeed W, Goodwin A, Kromplewski M, Medina D, Xiong H, Krivoshik A, Widemann B, Adamson PC, Balis FM: Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors. Cancer Chemother Pharmacol
    
    

return to the top